ArticleCancer medicine2025
Changes in Breast and Cervical Cancer Incidence by Stage at Diagnosis During the COVID-19 Pandemic in Utah.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe COVID-19 pandemic caused unprecedented disruptions in healthcare access, resulting in significant delays in breast and cervical cancer screening and diagnostic services. This study examined whether there were changes in the stage of diagnosis for breast and cervical cancers diagnosed among Utah women during the pandemic compared to years prior to the pandemic.
methodsPatients included adult females with a new breast or cervical cancer diagnosis reported to the Utah Cancer Registry, diagnosed from January 2020 to December 2021 (pandemic time period) or between January 2018 and December 2019 (pre-COVID-19). We calculated age-adjusted incidence rates and incidence rate ratios (IRRs) with 95% confidence intervals (CI) to compare stage at diagnosis and sociodemographic factors between time periods.
resultsA total of 308 cervical cancer cases and 8215 breast cancer cases were diagnosed throughout the duration of the study. Overall incidence of cervical cancer was higher during the pandemic, driven primarily by distant-stage disease incidence, which was more than three times higher than before the pandemic (IRR, 3.11; 95% CI, 1.67-5.79). Non-Hispanic (NH) White women were significantly more likely to be diagnosed with late-stage cervical cancer (IRR, 1.60; 95% CI, 1.12-2.30) during the pandemic compared to pre-pandemic. Local-stage breast cancer incidence decreased slightly during the pandemic compared to pre-pandemic (IRR, 0.93; 95% CI, 0.88-0.99). Hispanic women saw a slight increase in late-stage breast cancer incidence during the pandemic compared to before the pandemic (IRR, 1.31; 95% CI, 1.03-1.67).
conclusionsWe saw a significant increase in the incidence of late-stage cervical cancer during the pandemic compared with pre-pandemic. Conversely, while local-stage breast cancer incidence was slightly lower during COVID-19 compared with pre-COVID-19, no difference was observed among all other stages. More time is needed to assess the full impact of COVID-19 on breast and cervical cancer trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.